ERBB2 and breast cancer: Accordingly, the endoplasmic reticulum stress-inducing anticancer drug Bortezomib showed synergistic inhibition of ErbB2-overexpressing breast cancer cell proliferation when combined with ErbB2-targeted humanized antibody Trastuzumab.